Mildronat GX is prescribed in complex therapy: with ischemic heart disease (including angina pectoris, myocardial infarction); with reduced performance or physical overstrain (for example, y athletes); with chronic heart failure; with dyshormonal cardiomyopathy; with acute / chronic disorders of cerebral blood supply (stroke, cerebrovascular insufficiency); with thrombosis of the central retinal vein, its branches; with hemophthalmos (vitreous hemorrhage); with retinal hemorrhage; with retinopathy (diabetic, hypertensive); with withdrawal syndrome (in the complex treatment of alcoholism).
Mildronat GX composition active substance: meldonium phosphate;
1 tablet contains meldonium phosphate (in terms of meldonium) 500 mg;
Excipients: mannitol (E 421), povidone, potato starch, silicon dioxide, microcrystalline cellulose, magnesium stearate.
It is a remedy that improves metabolic processes. The drug restores the balance between the need for oxygen and its delivery to the cells, eliminates the accumulated toxic products of cellular metabolism. Also has a tonic effect. In the case of heart failure, it increases the contractility of the myocardium, reduces the incidence of angina attacks, and increases exercise tolerance. In case of cerebral circulation ischemic disorders, it improves blood flow in the ischemic focus, promotes blood redistribution in favor of the area suffering from a lack of oxygen. The drug helps to eliminate functional disorders of the nervous system.
Mildronat GX is prescribed in complex therapy:
- with ischemic heart disease (including angina pectoris, myocardial infarction);
- with reduced performance or physical overstrain (for example, y athletes);
- with chronic heart failure;
- with dyshormonal cardiomyopathy;
- with acute / chronic disorders of cerebral blood supply (stroke, cerebrovascular insufficiency);
- with thrombosis of the central retinal vein, its branches;
- with hemophthalmos (vitreous hemorrhage);
- with retinal hemorrhage;
- with retinopathy (diabetic, hypertensive);
- with withdrawal syndrome (in the complex treatment of alcoholism).
Mildronat GX should not be prescribed:
- with intolerance to the components;
- with increased intracranial pressure (with impaired venous outflow, the growth of intracranial tumors).
There is insufficient data on the use of the drug in children.
Application during pregnancy and lactation
The safety of use during these periods has not been proven.
Method of administration and dosage
Mildronat GX is administered orally.
- For cardiovascular diseases, 500–1000 mg / day is indicated. The standard course is 4-6 weeks.
- With cardialgia (pain in the heart) against the background of dyshormonal myocardial dystrophy – 250 mg x 2 times / day. Standard course – 12 days.
- In acute disorders of cerebral circulation, 500–1000 mg / day is indicated. The general course is 4-6 weeks. For chronic – 500 mg / day, course – 4-6 weeks.
- Repeated courses (2-3 times a year) are allowed after consultation with a doctor.
- For mental / physical overload, 250 mg x 4 times / day is indicated, the course of treatment is 10-14 days. If necessary, repeat the treatment in 2–3 weeks.
- Athletes are prescribed 500-1000 mg x 2 times / day by mouth before training. Duration of taking Mildronate GX in the preparatory period is 14-21 days, in the competitive period – 10-14 days.
- In chronic alcoholism, 500 mg x4 times / day is prescribed, the course of treatment is 7-10 days.
In view of the stimulating effect, the medicine is recommended to be taken in the morning.
Overdose cases are not known. The drug is low-toxic and does not cause adverse reactions dangerous to human health, even in case of an overdose.
Possible tachycardia, agitation, fluctuations in blood pressure, allergic reactions (exanthema, angioedema, urticaria, shock), dyspeptic symptoms.
Storage conditions and periods
Mildronat GX must be stored in its original packaging for no more than 2 years.
Temperature range: within 15-25 ° C. Protect from moisture.
Parents have a responsibility to ensure the safety of children by limiting their access to medicine.